MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage ...

MSD is reported to have been negotiating with Swiss biotech MoonLake Immunotherapeutics over a takeover deal – estimated to be worth more than $3 billion – according to media reports. The Financial ...

United States 2-Year Bond Yield Stay on top of current and historical data relating to U.S. 2-Year Bond Yield. By the definition, this two year term treasury note is intended as a way to fund U.S.

MSD's booth is seen during an expo in Shanghai in November. [PHOTO/CHINA DAILY] With a long-term commitment to the Chinese market, United States-based global pharmaceutical company MSD plans to ...